Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

NCT06891560 Phase 2 RECRUITING

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	RECRUITING
Enrolment	34
Start date	2025-03-31
Completion	2027-03

Conditions

• Adenoid Cystic Carcinoma

Interventions

• Enfortumab Vedotin

Primary outcomes

• best overall response rate — 1 year
  BOR; CR+PR by RECIST v1.1

Countries

United States